drugset / Trial / NCT01206595

Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy

NCT01206595

Phase 2 Completed 58 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to determine the appropriate dose of SKY0402 administered as a nerve block for the management of postoperative pain following bunionectomy.

Timeline

Start
2005-03
Primary completion
2006-03
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 125 mg Other
Comparator SKY0402 Unknown 175 mg Other
Comparator SKY0402 Unknown 225 mg Other
Comparator SKY0402 Unknown 350 mg Other

Indications

No indication recorded.